血清胸苷激酶1活性在激素受体阳性转移性乳腺癌患者中的预后作用:EFECT随机III期临床试验分析
该研究基于EFECT随机双盲试验存档血清,回顾性评估血清胸苷激酶1活性(sTKa)与激素受体阳性转移性乳腺癌内分泌治疗结局的相关性。基线sTKa低者中位至进展时间5.03个月,高于高者的2.57个月(P<0.0001);治疗中sTKa升高者中位至进展时间3.39个月,短于未升高者的5.39个月(P=0.0045)。作者认为sTKa是潜在的循环预后标志物,需独立验证。
要点
- 基线sTKa低者中位至进展时间5.03个月,高者2.57个月(P<0.0001)。
- 治疗中sTKa升高者中位至进展时间3.39个月,未升高者5.39个月(P=0.0045)。
- 校正主要预后因素后,sTKa仍为独立标志物;结果需独立验证。
核心结论
- sTKa是接受内分泌治疗的晚期乳腺癌患者潜在的循环预后标志物。
- sTKa可能有助于 upfront 识别内分泌治疗耐药和早期治疗阳性反应。
- 作者认为需对上述结果进行独立验证。
研究设计与样本
- EFECT为双盲、双模拟随机试验,比较氟维司群与依西美坦用于非甾体芳香化酶抑制剂治疗后进展的绝经后晚期乳腺癌患者。
- 本研究对EFECT存档血清进行回顾性分析,用DiviTum®检测基线、内分泌治疗3个月和6个月及疾病进展时的sTKa。
主要发现
- 基线sTKa低者中位至进展时间5.03个月(95%CI 3.91-5.89),基线sTKa高者2.57个月(95%CI 2.04-3.52),P<0.0001。
- 治疗中sTKa较基线升高者中位至进展时间3.39个月(95%CI 2.14-4.11),未升高者5.39个月(95%CI 4.01-6.68),P=0.0045。
- 在EFECT各治疗组中观察到相似结果。
- 校正主要预后因素后,sTKa仍为独立标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需对上述结果进行独立验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thymidine kinase 1 (TK1) plays a critical role in DNA synthesis and cell proliferation. Recent studies have shown potential for serum TK1 activity (sTKa) as a prognostic marker and indicator of early response to endocrine therapy in advanced breast cancer. The aim of this study is to assess the correlation between sTKa and patient outcome. PATIENTS AND METHODS: The Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) was a double-blind, double-dummy, randomised trial of fulvestrant versus exemestane after progression on non-steroidal aromatase inhibitor therapy, in postmenopausal women with advanced breast cancer. Retrospective analyses of serum archived from EFECT were conducted. sTKa was assessed using the DiviTum® assay on samples collected at baseline, after three and six months of endocrine therapy, and at disease progression. RESULTS: The median time to progression (mTTP) for patients with low baseline sTKa levels was 5.03 months (95% confidence interval [CI]: 3.91-5.89) versus 2.57 months (95% CI: 2.04-3.52) in patients with high sTKa baseline levels (P < 0.0001). On treatment, patients whose sTKa increased from baseline had a significantly shorter mTTP (3.39 months, 95% CI: 2.14-4.11) than those without an sTKa increase (5.39 months, 95% CI: 4.01-6.68) (P = 0.0045). Similar results were observed in the separate EFECT treatment arms. After adjusting for major prognostic factors, sTKa remained an independent marker. CONCLUSION: sTKa is a potential circulating prognostic marker in patients with advanced breast cancer treated with endocrine therapy. It may also represent a tool for upfront identification of endocrine therapy resistance and early positive response to therapy. Independent validation of these results is warranted.
引用
- McCartney A, Biagioni C, Schiavon G, et al. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). Eur J Cancer. 2019. PMID: 31059974. doi:10.1016/j.ejca.2019.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。